Alaunos Therapeutics, Inc. is a Houston-based biotechnology company developing cell therapies, particularly CAR-T therapies, with a focus on oncology and immunotherapy.

# Company Summary: Alaunos Therapeutics, Inc.

**Overview:**  
Alaunos Therapeutics, Inc. is a biotechnology company focused on the development of cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapies. The company is engaged in advancing its proprietary platforms and therapies, primarily in the areas of oncology and immunotherapy.

**Key Details:**  
- **Location:** Houston, Texas  
- **Principal Offices:** 2617 Bissonnet Street, Suite 233, Houston, TX 77005  
- **Telephone:** (346) 355-4099  
- **Stock Information:**  
  - Registered on Nasdaq Capital Market  
  - Trading Symbol: TCRT

**Financials (as of December 31, 2024):**  
- **Revenue:** No specific revenue figures are provided in the document.  
- **Net Income:** Losses reported; for example, the net loss for 2024 is indicated by a negative total shareholder return of -$4.679 million, with no positive income reported.  
- **Market Capitalization:** Approximately $10,801,553 as of June 30, 2024 (based on 1,543,079 shares at $7.00 per share).  
- **Outstanding Shares:** 1,639,521 shares as of April 30, 2025.

**Employees:**  
- The company structure includes executive officers and a small board of directors. Specific employee counts are not disclosed.

**Customers:**  
- No specific information about the number of customers has been provided.  
- The company engages in strategic collaborations and licensing agreements, including a joint venture with TriArm Therapeutics Ltd., which was dissolved in 2023.

**Business Focus & Activities:**  
- Developing **CAR-T therapies** using the Sleeping Beauty gene transfer platform.  
- Conducting clinical trials in China through Eden BioCell, a joint venture with TriArm (dissolved in 2023).  
- Exploring strategic options such as mergers, acquisitions, licensing, and partnerships to advance its pipeline.  
- Engaged in licensing and collaboration agreements with institutions like the National Cancer Institute and the University of Texas MD Anderson Cancer Center.  
- Actively working on in-licensing opportunities in obesity, oncology, and virology.  

**Corporate Actions & Initiatives:**  
- Wind-down of the TCR-T Library Phase 1/2 trial announced in August 2023.  
- Significant cost reduction with a workforce reduction of approximately 95%.  
- Engaged Cantor Fitzgerald & Co. as a strategic advisor.  

**Other Notes:**  
- The company has a small, specialized team with a focus on research and development in cell therapies.  
- No specific data on the number of active customers, revenue, or income figures beyond net losses and market value is provided.

A clinical-stage oncology-focused cell therapy company specializing in T-cell receptor engineered therapies for solid tumors.

# Company Overview

**Business Focus**:  
The company is a clinical-stage oncology-focused cell therapy company that was primarily involved in developing adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T). These therapies are designed to treat multiple solid tumor types in large cancer patient populations facing unmet clinical needs.

## Key Technologies and Initiatives
- **TCR Library**: The company has developed a TCR library that targets shared hotspot mutations found in key oncogenic genes such as KRAS, TP53, and EGFR. These mutations lead to neoantigens, which can be targeted by T cells.
  
- **Sleeping Beauty Gene Transfer Platform**: The proprietary non-viral gene transfer platform enables the incorporation of TCRs into T cells through a process called transposition, utilizing a specific enzyme referred to as a transposase. This platform aims to simplify and scale the manufacturing of TCR-T cell therapies.

- **hunTR® Discovery Engine**: A robust engine that utilizes state-of-the-art bioinformatics and next-gen sequencing to identify new TCRs rapidly, aimed at maximizing the breadth of the TCR library.

## Clinical Trials
- **TCR-T Library Phase 1/2 Trial**: The company began this clinical trial in partnership with The University of Texas MD Anderson Cancer Center, targeting 12 TCRs reactive to mutated KRAS, TP53, and EGFR across solid tumors like non-small cell lung, colorectal, pancreatic, and endometrial cancers. 

- **Trial Results** (as of the latest available data):
  - **Patients Treated**: 8
  - **Response Rates**: 13% overall response rate; 87% disease control rate among evaluable patients.
  - One patient experienced a partial response with six months of progression-free survival.

## Current Status and Financials
- **Workforce**: The company has drastically reduced its workforce by approximately 95% as part of a strategic reprioritization announced in August 2023. As of March 1, 2024, only 1 full-time employee remains.
  
- **Revenue and Income**: The company has historically not generated significant revenue; it reported a net loss of $35.1 million for the year ended December 31, 2023, with an accumulated deficit of approximately $915.8 million since its inception in 2003. As of December 31, 2023, cash and cash equivalents stood at around $6.1 million, allowing operations to continue into the third quarter of 2024.

- **Customers**: The company's focus is primarily on treating patients with advanced cancer, with solid tumors representing approximately 90% of new cancer diagnoses in the U.S. around 2 million cases and 610,000 deaths from cancer estimated for 2023.

## Strategic Alternatives
The company is exploring strategic alternatives, including potential mergers, acquisitions, or partnerships, as part of its current restructuring strategy following the wind-down of its major trial and clinical programs.

Alaunos Therapeutics, Inc.

10-K / April 30, 2025

10-K / April 1, 2024

10-K / April 30, 2025

Company Summary: Alaunos Therapeutics, Inc.